Andrew Lim

1.0k total citations
21 papers, 103 citations indexed

About

Andrew Lim is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Andrew Lim has authored 21 papers receiving a total of 103 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 6 papers in Genetics and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Andrew Lim's work include Multiple Myeloma Research and Treatments (7 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Acute Myeloid Leukemia Research (4 papers). Andrew Lim is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Acute Myeloid Leukemia Research (4 papers). Andrew Lim collaborates with scholars based in Australia, United Kingdom and France. Andrew Lim's co-authors include David Ritchie, Jeff Szer, Gábor Mikala, Brent Chesson, Ivan Špıčka, Ashish Bajel, Tomas Kron, A. Wirth, Marie‐Laure Risse and Andrew W. Roberts and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Andrew Lim

20 papers receiving 103 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Lim Australia 7 65 46 31 24 16 21 103
Alina Striha United Kingdom 6 114 1.8× 78 1.7× 91 2.9× 27 1.1× 12 0.8× 15 147
Donatella Russo Italy 7 31 0.5× 11 0.2× 12 0.4× 34 1.4× 12 0.8× 14 93
Helen Higgins United Kingdom 6 20 0.3× 64 1.4× 17 0.5× 15 0.6× 9 0.6× 19 112
Eugenio Piro Italy 7 76 1.2× 51 1.1× 49 1.6× 13 0.5× 19 1.2× 15 115
Mats Hardling Sweden 5 44 0.7× 22 0.5× 19 0.6× 16 0.7× 20 1.3× 6 76
Atsushi Marumo Japan 6 47 0.7× 12 0.3× 8 0.3× 8 0.3× 13 0.8× 20 71
Arnaud Lesegretain United States 6 69 1.1× 45 1.0× 52 1.7× 30 1.3× 22 1.4× 20 169
Habib El‐Khoury United States 6 60 0.9× 28 0.6× 32 1.0× 6 0.3× 21 1.3× 17 102
Kristin A. Rand United States 5 32 0.5× 34 0.7× 44 1.4× 52 2.2× 8 0.5× 6 145
Grzegorz Charliński Poland 8 70 1.1× 62 1.3× 56 1.8× 6 0.3× 21 1.3× 23 132

Countries citing papers authored by Andrew Lim

Since Specialization
Citations

This map shows the geographic impact of Andrew Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Lim more than expected).

Fields of papers citing papers by Andrew Lim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Lim. The network helps show where Andrew Lim may publish in the future.

Co-authorship network of co-authors of Andrew Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Lim. A scholar is included among the top collaborators of Andrew Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Lim. Andrew Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Špıčka, Ivan, Philippe Moreau, Thomas G. Martin, et al.. (2022). Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis. European Journal Of Haematology. 109(5). 504–512. 13 indexed citations
2.
Façon, Thierry, Philippe Moreau, Thomas G. Martin, et al.. (2022). Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematological Oncology. 40(5). 1020–1029. 11 indexed citations
3.
Façon, Thierry, Philippe Moreau, Thomas Martin, et al.. (2021). Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.. Journal of Clinical Oncology. 39(15_suppl). 8026–8026. 7 indexed citations
4.
5.
Façon, Thierry, Philippe Moreau, Thomas G. Martin, et al.. (2021). MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis. Clinical Lymphoma Myeloma & Leukemia. 21. S420–S420. 1 indexed citations
6.
Špıčka, Ivan, Philippe Moreau, Thierry Façon, et al.. (2021). Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.. Journal of Clinical Oncology. 39(15_suppl). 8042–8042. 8 indexed citations
7.
8.
Wong, Eric, et al.. (2020). Severity of mucositis during allogeneic transplantation impacts post-transplant cyclosporin absorption. Bone Marrow Transplantation. 55(9). 1857–1859. 1 indexed citations
9.
Canet, Emmanuel, Rinaldo Bellomo, David McD Taylor, et al.. (2020). Prognostic performance of qSOFA in oncology patients admitted to the emergency department with suspected infection. Asia-Pacific Journal of Clinical Oncology. 17(1). 94–100. 3 indexed citations
10.
Chua, Chong Chyn, Lan Zhang, Andrew Lim, et al.. (2019). Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. Leukemia & lymphoma. 61(4). 848–854. 1 indexed citations
11.
12.
Mastaglio, Sara, Eric Wong, Travis Perera, et al.. (2018). The Impact of Vitamin D Replacement on Survival, Relapse and GvHD after Allogeneic Stem Cell Transplantation: A Matched Cohort Analysis. Bone Marrow Transplantation. 53. 1 indexed citations
13.
Ball, Daniel, Shalini Vinod, Scott Babington, et al.. (2017). MA 13.07 A Randomized Trial of SABR vs Conventional Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: TROG09.02 (CHISEL). Journal of Thoracic Oncology. 12(11). S1853–S1853. 26 indexed citations
14.
15.
Perera, Travis, et al.. (2015). The Relationship Between Pre-Transplant 25-Hydroxy-Vitamin D Levels, Survival and Graft-Versus-Host Disease, in Allogeneic Haematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 21(2). S303–S303. 6 indexed citations
16.
Lim, Andrew, et al.. (2014). Validating the Allogeneic Stem Cell Transplantation Disease Risk Index. Transplantation. 99(1). 128–132. 9 indexed citations
17.
Lim, Andrew, et al.. (2014). Causes and Effects of Methotrexate Dose Alterations in Allogeneic Hematopoietic Cell Transplantation. Blood. 124(21). 2460–2460. 1 indexed citations
18.
19.
Lim, Andrew, Mark Speechley, & Paul C. Adams. (2014). PredictingC282YHomozygote Genotype for Hemochromatosis Using Serum Ferritin and Transferrin Saturation Values from 44,809 Participants of the HEIRS Study. Canadian Journal of Gastroenterology and Hepatology. 28(9). 502–504. 3 indexed citations
20.
Lim, Andrew, Jan Storek, Marnie Collins, et al.. (2013). High Donor and Recipient Age Are Not Risk Factors for Chronic Graft-Versus-Host Disease in the Setting of Anti-Thymocyte Globulin-Conditioned Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 19(2). S334–S334. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alina Striha Breakdown of academic impact, for papers by Donatella Russo Breakdown of academic impact, for papers by Helen Higgins Breakdown of academic impact, for papers by Eugenio Piro Breakdown of academic impact, for papers by Mats Hardling Breakdown of academic impact, for papers by Atsushi Marumo Breakdown of academic impact, for papers by Arnaud Lesegretain Breakdown of academic impact, for papers by Habib El‐Khoury Breakdown of academic impact, for papers by Kristin A. Rand Breakdown of academic impact, for papers by Grzegorz Charliński
Rankless by CCL
2026